Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 13/20 | 0.51 |
| ▸ | MTTP | P55157 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133101 | 0.88 | CRACR2A (0.56) | NPY2RMTTPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5133040 | 0.85 | CHRM5 (0.58) | KDM4ENPY2RNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5083802 | 0.79 | NPY2R (0.80) | NPY2RMTTP | |
| SCHEMBL5133152 | 0.76 | KDM4E (0.52) | KDM4ENPY2RNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5131965 | 0.75 | RAB9A (0.60) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5131900 | 0.71 | NPY2R (0.56) | KDM4ENPY2R | |
| SCHEMBL3657655 | 0.71 | NPY2R (0.63) | NPY2RMTTP | |
| SCHEMBL1173912 | 0.70 | NPY2R (0.65) | NPY2RMTTPHTTMAPT | |
| SCHEMBL5083818 | 0.69 | NPY2R (0.80) | NPY2RMTTP | |
| SCHEMBL5129718 | 0.69 | NPC1 (0.52) | KDM4ENPY2RMTTPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | KDM4E 1365/4885NPY2R 1/4885MTTP 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.